MagForce AG Announces that Kiel University Hospital (UKSH) has Initiated Commercial NanoTherm(TM) Treatment for Brain Cancer
March 27 2015 - 04:11AM
Business Wire
MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN:
DE000A0HGQF5), a leading medical device company in the field of
nanomedicine focused on oncology, today announced that the
Department of Neurosurgery at Kiel University Hospital (UKSH),
headed by Professor Dr. Hubertus Maximilian Mehdorn, has initiated
NanoTherm(TM) therapy in the commercial setting for the treatment
of brain cancers.
After the start of commercial treatments of brain cancers at the
University Hospital in Munster in February, this marks another
milestone for MagForce with now two world class medical centers
offering NanoTherm(TM) therapy also in the commercial setting.
"Since we announced the first commercial patient in February
this year based on our European approval for the treatment of brain
cancer, we have observed a significantly increased interest of
patients, national as well as international, for the treatment with
our innovative NanoTherm(TM) therapy in Germany. We are especially
pleased with the successful interaction with the key opinion
leaders in the medical community. Preparations for the approval
process in the US both for brain cancer and prostate cancer are
well on track, hence, 2015 is set to be a transformational year for
MagForce, marking first commercial revenues and global expansion,"
commented Dr. Ben J. Lipps, CEO of MagForce AG and MagForce USA,
Inc.
About MagForce AG and MagForce USA, Inc.
MagForce AG, listed in the entry standard of the Frankfurt Stock
Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary
MagForce USA, Inc. is a leading medical device company in the field
of nanomedicine focused on oncology. The Group's proprietary
NanoTherm(TM) therapy enables the targeted treatment of solid
tumors through the intratumoral generation of heat via activation
of superparamagnetic nanoparticles. Mithril Capital Management, a
growth-stage technology fund founded by Ajay Royan and Peter Thiel,
along with MagForce AG, are investors and strategic partners in
MagForce USA, Inc.
NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are components
of the therapy and have received EU-wide regulatory approval as
medical devices for the treatment of brain tumors. MagForce,
NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are trademarks of
MagForce AG in selected countries.
For more information, please visit: www.magforce.com
Get to know our Technology: video (You Tube)
Stay informed and subscribe to our mailing list.
Disclaimer
This release may contain forward-looking statements and
information which may be identified by formulations using terms
such as "expects", "aims", "anticipates", "intends", "plans",
"believes", "seeks", "estimates" or "will". Such forward-looking
statements are based on our current expectations and certain
assumptions, which may be subject to a variety of risks and
uncertainties. The results actually achieved by MagForce AG may
substantially differ from these forward-looking statements.
MagForce AG assumes no obligation to update these forward-looking
statements or to correct them in case of developments, which differ
from those, anticipated.
Language: English Company: MagForce AG Max-Planck-Straße 3 12489
Berlin Germany Phone: +49 (0)30 308 380 0 Fax: +49 (0)30 308 380 99
E-mail: info@magforce.com
Internet: www.magforce.com
ISIN: DE000A0HGQF5 WKN: A0HGQF Listed: Regulated Unofficial Market
in Berlin, Dusseldorf, Stuttgart; Open Market (Entry Standard) in
Frankfurt
Anne HenneckeMC Services AGT +49 211 529252-22F +49 211
529252-29Email: anne.hennecke@mc-services.eu